Imjudo (tremelimumab) / Pfizer, AstraZeneca 
Welcome,         Profile    Billing    Logout  

170 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Imjudo (tremelimumab) / AstraZeneca, Pfizer
NCT04988945: TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma

Recruiting
2
33
RoW
TACE, SBRT, Durvalumab, Tremelimumab
The University of Hong Kong
HCC
12/24
12/26
NCT04499053: Durvalumab and Tremelimumab in Combination With Chemotherapy in Virus-infected Patients With Non-small Cell Lung Cancer

Recruiting
2
18
US
Durvalumab, Tremelimumab
Georgetown University, AstraZeneca
Carcinoma, Non-Small Cell Lung
12/24
12/24
NCT05864755: HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma

Recruiting
2
30
RoW
HAIC+Durvalumab+Tremelimumab+Bevacizumab
Tianjin Medical University Cancer Institute and Hospital
Unrescetable Hepatocellular Carcinoma
12/24
12/25
NCI-2018-01240, NCT03026062: Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recruiting
2
120
US
Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab
M.D. Anderson Cancer Center
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Fallopian Tube Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma
12/24
12/24
NCT02815995: Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes

Completed
2
56
US
Durvalumab, Tremelimumab
M.D. Anderson Cancer Center, MedImmune LLC
Advanced and/or Metastatic Sarcoma
06/24
06/24
NCI-2018-01581, NCT03606967: Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Recruiting
2
70
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI 4736, MEDI-4736, MEDI4736, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nab-paclitaxel, ABI 007, ABI-007, ABI007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Naveruclif, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Paclitaxel Nanoparticle Albumin-bound, Paclitaxel Protein-Bound, Protein-bound Paclitaxel, Personalized Synthetic Long Peptide Vaccine, Personalized SLP Vaccine, TSMA-based SLP Vaccine, TSMA-based Synthetic Long Peptide Vaccine, Tumor Specific Mutant Antigen-based Synthetic Long Peptide Vaccine, Poly ICLC, Hiltonol, Poly I:Poly C with Poly-L-Lysine Stabilizer, poly-ICLC, PolyI:PolyC with Poly-L-Lysine Stabilizer, Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose, Polyriboinosinic-Polyribocytidylic Acid-Polylysine Carboxymethylcellulose, Stabilized Polyriboinosinic/Polyribocytidylic Acid, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP 675, CP 675206, CP-675, CP-675,206, CP-675206, CP675, CP675206, Imjudo, Ticilimumab, Tremelimumab-actl
National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
12/24
12/24
MOST plus, NCT02029001: Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment

Recruiting
2
900
Europe
Nilotinib (400 mg BID), Open cohort, Everolimus (10 mg QD), Closed cohort, Sorafenib (400 mg BID), Lapatinib (1500 mg QD), Pazopanib (800 mg QD), Olaparib (300 mg BID), Durvalumab + Tremelimumab
Centre Leon Berard, National Cancer Institute, France
Malignant Solid Neoplasms
01/26
10/27
DUMELEP, NCT06045975: Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation

Recruiting
2
30
Europe
Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting
Assistance Publique - Hôpitaux de Paris, AstraZeneca
BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA
09/26
09/27
IMMUWIN, NCT04522544: Durvalumab and Tremelimumab in Combination With Either Y-90 SIRT or DEB-TACE for Intermediate Stage HCC

Recruiting
2
55
Europe
Tremelimumab, Durvalumab, Y-90 SIRT, DEB-TACE
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, AstraZeneca, Hannover Medical School
Hepatocellular Carcinoma Non-resectable, HCC
03/25
09/25
INFINITY, NCT04817826: TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC.

Checkmark Data from INFINITY trial in combination with tremelimumab in patients with gastric or gastroesophageal junction cancer at ASCO-GI 2023
Jan 2023 - Jan 2023: Data from INFINITY trial in combination with tremelimumab in patients with gastric or gastroesophageal junction cancer at ASCO-GI 2023
Recruiting
2
31
Europe
Durvalumab, Tremelimumab
Gruppo Oncologico del Nord-Ovest
Gastric Cancer, Microsatellite Instability
04/25
04/25
NCT03911557: Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

Active, not recruiting
2
14
US
Durvalumab and Tremelimumab
John L. Villano, MD, PhD
Tumor, Solid
06/25
06/25
NCT02938793: Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors

Recruiting
2
150
US
Durvalumab, MEDI4736, Tremelimumab, CP-675,206
Prisma Health-Upstate, AstraZeneca, MedImmune LLC
Cancer, Rare Disease
02/26
06/27
NCT05380713: ......SMARTEST Trial......

Recruiting
2
30
Canada
Cyclophosphamide, Tremelimumab, Durvalumab
University Health Network, Toronto, OICR
Mesothelioma, Malignant
07/25
10/28
NCT05451043: Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

Recruiting
2
62
Canada
Durvalumab, Imfinzi, Gemcitabine, Gemzar, Nab paclitaxel, Abraxane, Tremelimumab, Propranolol, Cisplatin
AHS Cancer Control Alberta
Pancreatic Cancer, Hepatocellular Cancer, Biliary Tract Cancer, Cholangiocarcinoma
10/25
10/28
NEOTOMA, NCT05440864: Durvalumab and Tremelimumab in Resectable HCC

Recruiting
2
28
Europe, Canada
Tremelimumab, Durvalumab
University Health Network, Toronto, Clinica Universidad de Navarra, Universidad de Navarra, University of Milan
Hepatocellular Carcinoma
11/25
11/26
NCT04238637: Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)

Recruiting
2
50
Europe
Durvalumab, Other Name: MEDI4736, Tremelimumab, Study treatment
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, AstraZeneca
Intrahepatic Cholangiocarcinoma
12/25
12/25
NCT05027425: Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

Recruiting
2
30
US
Durvalumab, MEDI4736, Tremelimumab, Liver Transplant
Davendra Sohal
Hepatocellular Carcinoma, Cirrhosis, Portal Hypertension
12/25
12/30
NCT05809869: Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma

Recruiting
2
25
RoW
Durvalumab, MEDI4736, Tremelimumab, Imjudo, Yttrium-90 radioembolisation
The University of Hong Kong, Queen Mary Hospital, Hong Kong
Hepatocellular Carcinoma
12/25
06/26
NCT03410615: Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC

Active, not recruiting
2
129
Europe, Canada
Radiation, Cisplatin, Durvalumab, Tremelimumab
Canadian Cancer Trials Group, AstraZeneca
Oropharyngeal Squamous Cell Carcinoma
01/26
07/26
CHESS, NCT03965468: Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC

Recruiting
2
96
Europe
Durvalumab, Imfinzi, Carboplatin, Paclitaxel, Stereotactic body radiation therapy (SBRT), Surgical resection - definitive local treatment., Radical radiotherapy - definitive local treatment., Tremelimumab
ETOP IBCSG Partners Foundation, AstraZeneca
Non-small Cell Lung Cancer, Stage IV, Oligometastasis
08/26
12/26
ChiCTR2200060662: A prospective, single-arm, multicenter phase II clinical study of SBRT in combination with tremelimumab, GM-CSF and tegeo for recurrent/metastatic nasopharyngeal carcinoma

Not yet recruiting
2
68
 
SBRT+GM-CSF+PD-1 inhibitor
Fujian Cancer Hospital; Fujian Cancer Hospital, none
recurrent/metastatic nasopharyngeal carcinoma
 
 
ESR-22-21719, NCT06017297: Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma

Recruiting
2
28
US
Durvalumab, Tremelimumab, Gemcitabine, Cisplatin, Surgical Resection
Georgetown University, AstraZeneca
Borderline Resectable Carcinoma, Biliary Tract Cancer
11/26
11/26
CORAL-Lung, NCT05000710: Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy

Recruiting
2
29
RoW
Durvalumab, Imfinzi, MEDI4736, Tremelimumab, Low dose irradiation
Sheba Medical Center, AstraZeneca, Rambam Health Care Campus, Tel-Aviv Sourasky Medical Center
Metastatic or Locally Advanced NSCLC
12/26
12/26
ROWAN, NCT05063565: TheraSphere With Durvalumab and Tremelimumab for HCC

Recruiting
2
100
Europe, US
TheraSphere Y-90 glass microsphere therapy, Durvalumab (Imfinzi) immunotherapy, Tremelimumab immunotherapy
Boston Scientific Corporation, Biocompatibles UK Ltd
Hepatocellular Carcinoma
06/27
06/27
MONTBLANC, NCT05844046: Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients

Recruiting
2
83
Europe
durvalumab, tremelimumab, bevacizumab
Enrico De Toni
Hepatocellular Carcinoma
12/26
12/26
NCT04430452: Hypofractionated Radiotherapy Followed by Durvalumab With or Without Tremelimumab for Liver Cancer After Progression on PD-1 Inhibition

Recruiting
2
21
US
Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Hypofractionated Radiation Therapy, Hypofractionated Radiotherapy, hypofractionation, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab
Mary Feng, MD, AstraZeneca
Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8
02/27
02/27
2017-001857-14: A phase I/II basket trial evaluating a combination of Metronomic Oral Vinorelbine plus anti-PD-L1/anti-CTLA4 ImmunothErapy in patients with advanced solid tumours.

Not yet recruiting
1/2
159
Europe
Durvalumab, Tremelimumab, MEDI4736, Capsule, soft, Solution for injection, NAVELBINE
UNICANCER, Astra Zeneca, Pierre Fabre, Programme Hospitalier de Recherche Clinique
Patients with Histologically confirmed locally advanced or metastatic solid tumours, resistant to conventional therapies, and candidate to experimental therapy by local clinical board, from the following primary tumours: head and neck, prostate, cervix, and breast cancers, as well as miscellaneous malignancies with high mutational load., Patients with locally advanced or metastatic solid tumours, Diseases [C] - Cancer [C04]
 
 
NCT02499328 / 2015-002525-19: Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

Checkmark In combination with tremelimumab for metastatic SCCHN
Jan 2019 - Jan 2019: In combination with tremelimumab for metastatic SCCHN
Checkmark In combination with danvatirsen for metastatic squamous cell carcinoma of the head and neck
Oct 2018 - Oct 2018: In combination with danvatirsen for metastatic squamous cell carcinoma of the head and neck
Active, not recruiting
1/2
340
Europe, US
AZD9150, MEDI4736, AZD5069, tremelimumab (treme)
AstraZeneca, MedImmune LLC
Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck
02/20
03/25
NCT03206073: A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer

Checkmark Results in combination with Pexa-Vec with failed MSS and MSI-H colorectal cancer
Jan 2019 - Jan 2019: Results in combination with Pexa-Vec with failed MSS and MSI-H colorectal cancer
Completed
1/2
34
US
Durvalumab, MEDI-4736, Tremelimumab, CP-675,206, Pexa-Vec, Pexa-Vec, INN pexastimogene devacirepvec
National Cancer Institute (NCI)
Colorectal Cancer, Colorectal Carcinoma, Colorectal Adenocarcinoma, Refractory Cancer, Colorectal Neoplasms
09/20
06/22
NCT02571725: PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

Active, not recruiting
1/2
50
US
Olaparib, AZD-2281, Lynparza, Tremelimumab, CP-675,206
New Mexico Cancer Care Alliance
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
12/20
07/27
MOVIE, NCT03518606: Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours

Active, not recruiting
1/2
126
Europe
Durvalumab + Tremelimumab + metronomic Vinorelbine
UNICANCER, National Cancer Institute, France, AstraZeneca, Pierre Fabre Laboratories
Advanced Solid Tumours, Breast Cancer, Head and Neck Cancer, Cervix Cancer, Prostate Cancer
04/22
12/24
Rideau, NCT05120622: Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer

Withdrawn
1/2
48
Canada
Tremelimumab
University of British Columbia
Bladder Cancer, High-Risk Cancer, Tremelimumab, Durvalumab, Non-muscle Invasive
05/22
05/22
NCT03837899 / 2018-003118-42: Durvalumab and Tremelimumab for Pediatric Malignancies

Active, not recruiting
1/2
56
Europe, US
Durvalumab / Tremelimumab Combination Therapy, durvalumab: Imfinzi, MEDI4736, tremelimumab: CP-675,206
AstraZeneca
Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies
02/23
12/24
DUTRELASCO, NCT03784066: Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity

Active, not recruiting
1/2
21
Europe
Durvalumab, Durvalumab + Tremelimumab
Universitaire Ziekenhuizen KU Leuven, AstraZeneca, European Organisation for Research and Treatment of Cancer - EORTC, Vlaams Instituut voor Biotechnologie (VIB)
Oral Cavity Squamous Cell Carcinoma
03/25
03/26
ABBIMUNE, NCT03212469: A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer

Active, not recruiting
1/2
54
Europe
Durvalumab, Tremelimumab, SBRT
Gustave Roussy, Cancer Campus, Grand Paris
Head and Neck Squamous Cell Carcinoma, Lung Cancer, Oesophageal Cancer
06/24
12/24
NCT02535078 / 2015-002971-12: Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma

Checkmark OS data from trial in combination with durvalumab and tremelimumab for cutaneous melanoma
Jun 2022 - Jun 2022: OS data from trial in combination with durvalumab and tremelimumab for cutaneous melanoma
Completed
1/2
113
US
Tebentafusp (IMCgp100), durvalumab, MEDI4736, tremelimumab
Immunocore Ltd, AstraZeneca
Malignant Melanoma
06/23
09/23
NCT03751761: GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study

Completed
1/2
58
RoW
durvalumab, tremelimumab, paclitaxel
Asan Medical Center, Hallym University Medical Center, Seoul National University Bundang Hospital
Metastatic Gastric Cancer
08/23
08/23
NCT03283605: Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas

Active, not recruiting
1/2
45
Canada
SBRT, Durvalumab, Tremelimumab
Centre hospitalier de l'Université de Montréal (CHUM), AstraZeneca
Head and Neck Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma
07/24
12/24
ICRA, NCT03871036: Improve Checkpoint-blockade Response in Advanced Urothelial Cancer

Active, not recruiting
1/2
53
Europe
Tremelimumab, Ticilimumab, CP-675,206, Durvalumab, Imfinzi, MEDI4736, Paclitaxel, Taxol
The Netherlands Cancer Institute, AstraZeneca
Urothelial Carcinoma
09/23
01/25
SCCHN, NCT03618134: Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner

Terminated
1/2
19
US
Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Modified Radical Neck Dissection, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy, Transoral Robotic Surgery, TORS, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab
Jonsson Comprehensive Cancer Center, AstraZeneca
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus Positive, Oropharyngeal Squamous Cell Carcinoma, p16 Positive Neoplastic Cells Present, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
06/23
06/23
ICC, NCT04989218: Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma

Terminated
1/2
1
US
Novel combination of chemotherapy and immunotherapy, Cisplatin (Platinol), Gemcitabine (Gemzar), Durvalumab (Imfimzi), Tremelimumab
University of Alabama at Birmingham
Cholangiocarcinoma
03/24
05/24
INeOV, NCT03249142: Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer

Active, not recruiting
1/2
69
Europe
ARM A Durvalumab/chemotherapy association, ARM B Durvalumab/Tremelimumab/chemotherapy association
ARCAGY/ GINECO GROUP, AstraZeneca
Ovarian Cancer
12/24
12/24
NEMIO, NCT03549715: NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma

Active, not recruiting
1/2
121
Europe
Durvalumab, MEDI4736, Tremelimumab, CP-675,206, MVAC Protocol, ddMVAC
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Infiltrating Bladder Urothelial Carcinoma
06/24
09/25
NCT02962063: Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer

Recruiting
1/2
78
US
durvalumab, (MEDI4736), carboplatin AUC 2/paclitaxel, External beam radiation (EBRT), esophagogastrectomy, Tremelimumab
Memorial Sloan Kettering Cancer Center, AstraZeneca
Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
11/24
11/24
CAMILLA, NCT03539822: Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

Checkmark Data from CAMILLA trial in combination with durvalumab in advanced CRC at ASCO GI 2022
Jan 2022 - Jan 2022: Data from CAMILLA trial in combination with durvalumab in advanced CRC at ASCO GI 2022
Active, not recruiting
1/2
117
US
Cabozantinib, multi-tyrosine kinase Inhibitor, Durvalumab, anti-Programmed cell death protein 1 (PD-L1) inhibitor, Tremelimumab, Anti-CTLA4 inhibitor
Anwaar Saeed, AstraZeneca, Exelixis
Gastric Cancer, Esophageal Adenocarcinoma, Hepatocellular Carcinoma, Colorectal Cancer
11/26
11/27
ADAPT-BLADDER, NCT03317158: Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder

Recruiting
1/2
55
US
Durvalumab (Cohort 1-3), Imfinzi, External Beam Radiotherapy (EBRT), Bacillus Calmette-Guérin (BCG), Gemcitabine, Gemzar, Docetaxel, Taxotere, Tremelimumab, Durvalumab (Cohort 4/5), To be determined
Noah Hahn, M.D., AstraZeneca, Hoosier Cancer Research Network
Urothelial Carcinoma, Bladder Cancer
12/24
12/25
NCI-2018-01098, NCT03581487: Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

Active, not recruiting
1/2
40
US
Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Selumetinib, ARRY-142886, AZD6244, MEK inhibitor AZD6244, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
12/25
12/25
NCT05932199: Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma

Not yet recruiting
1/2
52
US
Durvalumab / tremelimumab, Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab
Baylor College of Medicine, Duke Cancer Institute
Mesothelioma
05/28
05/28
NEXIS, NCT03116529: Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma

Active, not recruiting
1/2
22
US
Combination Radiation, Immunotherapy, Surgery
University of Maryland, Baltimore, AstraZeneca, University of Arizona, West Penn Allegheny Health System
Soft Tissue Sarcoma
06/32
06/37
jRCT2031210046: A phase Ib study of durvalumab (MEDI4736) tremelimumab combined with particle therapy in advanced hepatocellular carcinoma patients with macrovascular invasion

Suspended
1b
15
Japan
Imfinzi (durvalumab) - AstraZeneca, Imjudo (tremelimumab) - AstraZeneca, Pfizer
Chiba university hospital, AstraZeneca K.K.
Hepatocellular carcinoma
 
 
NCT02071992: Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma

Not yet recruiting
1
24
US
Tremelimumab, CP-675,206, Ticilimumab, MEDI3617, MEDI-3617
F. Stephen Hodi, MD, MedImmune LLC
Metastatic Melanoma
06/17
02/19
NCT02537418: Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens

Active, not recruiting
1
153
Canada
durvalumab, tremelimumab
Canadian Cancer Trials Group, AstraZeneca
Solid Malignancies
07/18
12/24
NCI-2018-01189, NCT03132467: Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer

Completed
1
16
US
Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
01/19
05/24
NCT03275597: Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

Terminated
1
17
US
Durvalumab, 1428935-60-7, D10808, Tremelimumab, 745013-59-6, QEN1X95CIX, Stereotactic Body Radiotherapy, SRBT, stereotactic ablative radiotherapy, SABR
University of Wisconsin, Madison, AstraZeneca
Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage IV
07/20
07/20
NCT02141542: Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma

Hourglass Jan 2017 - Dec 2017 : Tremelimumab and MEDI3617 combination in unresectable melanoma
Completed
1
15
US
Tremelimumab, CP-675,206, Ticilimumab, MEDI3617, MEDI-3617
F. Stephen Hodi, MD, MedImmune LLC
Metastatic Melanoma
09/20
09/20
CLOVER, NCT03509012: Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors

Hourglass Nov 2021 - Dec 2021 : From CLOVER trial in combination with tremelimumab for solid tumors
Active, not recruiting
1
105
Europe, Japan, US, RoW
Durvalumab, MEDI4736, Tremelimumab, Cisplatin (dose level 4), Cisplatin (dose level 3), Carboplatin (dose level 1), Carboplatin (dose level 2), Etoposide (dose level 1), Etoposide (dose level 2), Paclitaxel, Pemetrexed, External beam radiation (dose level 1), External beam radiation (dose level 2), External beam radiation (hyperfractionated), Cisplatin (dose level 1), Cisplatin (dose level 2), External beam radiation (standard)
AstraZeneca
Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma
12/20
12/24
NCT03923270: Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

Active, not recruiting
1
25
US
Durvalumab, Imfinzi, MEDI4736, Tremelimumab, Olaparib Pill, Lynparza, MK-7339, Thoracic Radiotherapy
H. Lee Moffitt Cancer Center and Research Institute, AstraZeneca
Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer
06/23
08/24
NCT05928962: An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas

Enrolling by invitation
1
10
RoW
Recombinant Human Adenovirus Type 5 Injection, Tremelimumab
Fujian Cancer Hospital
Malignant Melanomas
08/23
10/24
NCT03452332: Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers

Completed
1
20
US
Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Laboratory Biomarker Analysis, Stereotactic Radiosurgery, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, Stereotactic Radiation Therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Advanced Cervical Adenocarcinoma, Advanced Vaginal Carcinoma, Advanced Vulvar Carcinoma, Human Papillomavirus-Related Cervical Squamous Cell Carcinoma, Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma, Metastatic Cervical Adenocarcinoma, Metastatic Cervical Carcinoma, Metastatic Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Metastatic Vaginal Adenocarcinoma, Metastatic Vaginal Carcinoma, Metastatic Vulvar Carcinoma, Recurrent Cervical Adenocarcinoma, Recurrent Cervical Carcinoma, Recurrent Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Recurrent Vaginal Carcinoma, Recurrent Vulvar Carcinoma, Stage III Cervical Cancer AJCC v8, Stage III Vaginal Cancer AJCC v8, Stage III Vulvar Cancer AJCC v8, Stage IIIA Cervical Cancer AJCC v8, Stage IIIA Vulvar Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IIIB Vulvar Cancer AJCC v8, Stage IIIC Vulvar Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Vaginal Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Vaginal Cancer AJCC v8, Stage IVA Vulvar Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Vaginal Cancer AJCC v8, Stage IVB Vulvar Cancer AJCC v8, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified, Vulvar Adenocarcinoma, Vulvar Squamous Cell Carcinoma
08/23
08/23
NCT02639026: Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

Completed
1
53
US
Radiotherapy, MEDI4736, Tremelimumab
Abramson Cancer Center at Penn Medicine
Metastatic, Melanoma, Non Small Cell Lung Cancer (NSCLC), Breast Cancer, Pancreatic Cancer
06/23
06/23
NCT04605731: Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer

Recruiting
1
32
US
Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab
City of Hope Medical Center, National Cancer Institute (NCI)
BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
12/24
12/24
RESOLVE, NCT05154994: Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in ARID1A Mutated Cancer Focus on Urothelial Carcinoma

Suspended
1
9
US
Belinostat, Beleodaq, PXD 101, PXD101, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736
University of Utah, National Cancer Institute (NCI)
Infiltrating Urothelial Carcinoma, Sarcomatoid Variant, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
11/24
11/26
NCT02812420: Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery

Active, not recruiting
1
54
US
Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Therapeutic Conventional Surgery, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Hydronephrosis, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant, Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant, Infiltrating Renal Pelvis Urothelial Carcinoma, Sarcomatoid Variant, Renal Pelvis Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage II Renal Pelvis Cancer AJCC v7, Stage II Ureter Cancer AJCC v7, Stage II Urethral Cancer AJCC v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Renal Pelvis Cancer AJCC v7, Stage III Ureter Cancer AJCC v7, Stage III Urethral Cancer AJCC v7, Stage IV Renal Pelvis Cancer AJCC v7, Stage IV Ureter Cancer AJCC v7, Stage IV Urethral Cancer AJCC v7, Ureter Urothelial Carcinoma, Urethral Urothelial Carcinoma
12/24
12/24
RAIDEN, NCT06058663: Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Recruiting
1
18
US
Angiography, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP-675, CP-675,206, CP-675206, Imjudo, Ticilimumab, Tremelimumab-actl, Yttrium-90 Microsphere Radioembolization, Yttrium Y 90 Microsphere Therapy, Yttrium-90 Radioembolization
Mayo Clinic, National Cancer Institute (NCI)
Locally Advanced Intrahepatic Cholangiocarcinoma, Oligometastatic Intrahepatic Cholangiocarcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Intrahepatic Cholangiocarcinoma
11/25
11/25
NCT05701488: SIRT With Tremelimumab and Durvalumab for Resectable HCC

Recruiting
1
20
US
Durvalumab, Imjudo, MEDI4736, Tremelimumab, Imfinzi, SIRT, Selective Internal Yttrium-90 Radioembolization
Jiping Wang, MD, PhD, AstraZeneca, Sirtex Medical
Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Cancer
10/25
10/25
NCT00584493: Treatment Use Study for Advanced Melanoma.

No Longer Available
N/A
US
CP-675,206
Pfizer
Advanced Unresectable Melanoma
 
 
MITRE, NCT04107168: Microbiome Immunotherapy Toxicity and Response Evaluation

Recruiting
N/A
1800
Europe
Nivolumab, Opdivo, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Durvalumab, Imfinzi, Tremelimumab, CP-675,206, Atezolizumab, Tecentriq, Bevacizumab, Avastin
CCTU- Cancer Theme, Microbiotica Ltd
Melanoma, Renal Cancer, Lung Cancer
07/24
07/25
NCT05667064: Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study

Recruiting
N/A
300
Japan
AstraZeneca
Unresectable Hepatocellular Carcinoma
12/26
12/26
NCT05826366: Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI

Active, not recruiting
N/A
296
Japan
AstraZeneca
Carcinoma, Non-Small-Cell Lung
11/25
11/25
REFINE-IO, NCT06117891: An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery

Recruiting
N/A
300
Europe, US, RoW
Atezolizumab, Bevacizumab, Durvalumab, Tremelimumab,
Bayer
Unresectable Hepatocellular Carcinoma
11/26
02/27
 

Download Options